Robin Shane Readnour - 19 Dec 2024 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Director
Signature
/s/ Eric Easom, Attorney-in-Fact for Robin Shane Readnour
Issuer symbol
ANTX
Transactions as of
19 Dec 2024
Net transactions value
$0
Form type
4
Filing time
23 Dec 2024, 18:32:55 UTC
Previous filing
10 Dec 2024
Next filing
23 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Award $0 +9,077 $0.000000 9,077 19 Dec 2024 Direct F1
holding ANTX Common Stock 582,288 19 Dec 2024 See Footnote F2, F3
holding ANTX Common Stock 652,573 19 Dec 2024 See Footnote F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
F2 MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC Venture Partners 2018, LP ("MGC 2018 LP") and MGC Venture Partners QP 2018 LP ("MGC 2018 QP"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities.
F3 Shares held directly by MGC 2018 LP.
F4 Shares held directly by MGC 2018 QP.